学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2017-06-23至2017-06-24 海口
Menu
报名参会
Sign up

已确认嘉宾Normal Guest

翁锦生

美国安德森癌症中心

TCR-T治疗血液肿瘤和实体肿瘤的临床前研究

翁锦生

演讲题目:TCR-T治疗血液肿瘤和实体肿瘤的临床前研究

美国安德森癌症中心

教育背景   
  医学学士  南昌大学,预防医学,

医学硕士  中山大学, 临床医学内科学

医学博士  德州农工大学医学中心, 肿瘤和干细胞系

    

工作经历
● 1994-1999  临床检验师,广东江门中心医院

●  2007-2008  博士后研究者, 贝勒医学院

●  2008-2011  博士后研究者, 美国安德森肿瘤中心

●  2011-现在  研究指导, 美国安德森肿瘤中心

    

   学会会员

  ●  美国生物化学与分子生物学学会副会员

  ●  美国肿瘤学会副会员

●  美国肿瘤学会会员

●  美国血液病学会会员

●  美国免疫学会会员

●  美国肿瘤免疫治疗协会会员

 

奖励

 ● 2004  美国生物化学与分子生物学学会研究生旅行奖

 ● 2005  德州农工大学医学部新生医学讨论会海报第一名

    ● 2006  美国生物化学与分子生物学学会研究生旅行奖

  ● 2011  美国血液病学会优秀文摘奖

 ● 2011  Margaret L. Kripke 特别优秀肿瘤免疫学者奖

    ● 2014  美国免疫学会新教师旅行奖

     

 专利

  TCL1 多肽在肿瘤免疫治疗中的应用(WO 2013075105 A3)

  TCL1 多肽在肿瘤免疫治疗中的应用(US 20140348902 A1)

 

 研究基金

 美国国立卫生研究院多发性骨髓瘤SPORE事业基金(2013-2014, 第一负责人)

   国际多发性骨髓瘤基金会新研究者基金(2014,第一负责人)  

   美国女士白血病基金(2014,第一负责人)

   美国国立卫生研究院多发性骨髓瘤SPORE事业基金(2014-2015, 第一负责人)

 

   发表文章

    1.Weng, J., Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti S, Gwak D, Popescu MS,

  Cha SC, Cooper LJ, Neelapu SS, Kwak LW. IL-15 enhances the anti-tumor effect of human

  antigen-specific CD8 T cells by cellular senescence delay Oncommunology 2016 Oct

  7; 5(12):e1237327. (IF:7.6, First and corresponding author ) 

    2.Weng, J., Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang 

  L, Yang J, Yi Q, Neelapu SS, Kwak LW. Targeting B-cell malignancies through human B-cell

  receptor specific CD4 T cells OncoImmunology 2016 Sep 19;5(11):e1232220. (IF:7.6, 

  First and corresponding author )

    3.Weng, J., Rawal, S., Chu, F., Park, H.J., Sharma, R., Delgado, D.A., Fayad, L., Fanale, M.,

  Romaguera, J., Luong, A., et al. 2012. TCL1: a shared tumor-associated antigen for  

  immunotherapy against B-cell lymphomas. Blood 120:1613-1623. (IF: 11.8)

4. Weng, J., Cha, S.C., Matsueda, S., Alatrash, G., Popescu, M.S., Yi, Q., Molldrem, J.J., Wang, M., Neelapu, S.S., and Kwak, L.W. 2011. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17:5945-5952. (IF:8.2)

5. Weng, J., Neelapu, S.S., Woo, A.F., and Kwak, L.W. 2011. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol 344:193-210. (IF:4.0, First and corresponding author)

6. Weng, J., Luo, J., Cheng, X., Jin, C., Zhou, X., Qu, J., Tu, L., Ai, D., Li, D., Wang, J., et al. 2008. Deletion of G protein-coupled receptor 48 leads to ocular anterior segment dysgenesis (ASD) through down-regulation of Pitx2. Proc Natl Acad Sci U S A 105:6081-6086. (IF:9.73)

7. Weng, J., Wang, J., Hu, X., Wang, F., Ittmann, M., and Liu, M. 2006. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer 118:1471-1480. (IF:5.0)

8. Weng, J., Wang, J., Cai, Y., Stafford, L.J., Mitchell, D., Ittmann, M., and Liu, M. 2005. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 113:811-818. (IF:5.0)

9. Weng, J., Ma, W., Mitchell, D., Zhang, J., and Liu, M. 2005. Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors. J Cell Biochem 96:1034-1048. (IF:3.4)

10. Weng, J., Wang, J., Cai, Y., Penland, R., Liu, M., and Ittmann, M. 2006. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate 66:847-857.(co-first author)(IF: 3.6)

11.    Yi T, Weng J, Siwko S, Luo J, Li D, Liu M. 2014. LGR4/GPR48 inactivation leads to aniridia- genitourinary anomalies-mental retardation syndrome defects.  J Biol Chem 289(13): 8767-80. (IF: 4.6)

12. Matsueda, S., Wang, M., Weng, J., Li, Y., Yin, B., Zou, J., Li, Q., Zhao, W., Peng, W., Legras, X., et al. 2012. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One 7:e45756. ( IF: 3.73)

13. Siwko, S., Lai, L., Weng, J., and Liu, M. 2013. Lgr4 in ocular development and glaucoma. J Ophthalmol 2013:987494. (IF:1.30)

14. Mitchell, D.C., Abdelrahim, M., Weng, J., Stafford, L.J., Safe, S., Bar-Eli, M., and Liu, M. 2006. Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J Biol Chem 281:51-58.(IF:4.6)

15.   Rodriguez M, Luo W, Weng J, Zeng L, Yi Z, Siwko S, Liu M. 2014. PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis.11;3:e114. doi: 10.1038/oncsis.2014.29 (IF=5.0)


编书

       Weng, J., Neelapu, S., Woo, A., and Kwak, L. 2011. Identification of Human Idiotype-Specific  

     T Cells in Lymphoma and Myeloma. In Cancer Immunology and Immunotherapy. G. Dranoff,

     editor: Springer Berlin Heidelberg. 193-210.

 



邀请函

下载邀请函
大会咨询
姓名 *

E-mail*

电话: *

消息: *

×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: